- Home
- NRSN vs DYAI Comparison
NRSN vs DYAI Comparison
Compare NRSN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRSN | DYAI |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 30.2M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NRSN | DYAI |
|---|---|---|
| Price | $0.88 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $3.00 |
| AVG Volume (30 Days) | 489.0K | ★ 526.2K |
| Earning Date | 04-06-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,342,195.00 |
| Revenue This Year | N/A | $12.52 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.71 |
| 52 Week High | $2.60 | $2.20 |
Technical Indicators
Market Signals| Indicator | NRSN | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 43.36 |
| Support Level | $0.86 | $0.89 |
| Resistance Level | $1.24 | $1.04 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 7.89 | 21.01 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.